# Omri Amirav-Drory

> Omri Amirav-Drory, Ph.D., is a General Partner at NFX leading NFX Bio, a pre-seed and seed venture fund focused on scientist-founders at the intersection of technology and biology. A former Fulbright Scholar and Stanford postdoc turned biotech entrepreneur, he co-founded Genome Compiler (acquired by Twist Bioscience), launched Tech.Bio, and now backs breakthrough life sciences companies while co-founding Renewal Bio - a longevity company building synthetic embryo-derived tissues to combat aging. His stated mission is ending involuntary death.

- **Role:** General Partner at NFX
- **Organizations:** NFX, NFX Bio, Renewal Bio, Tech.Bio, Genome Compiler (acquired), IndieBio, Alliance for Longevity Initiatives (A4LI), Lifeboat Foundation
- **From:** Israel
- **Nationality:** Israeli-American
- **Education:** B.S., Biochemistry and Molecular Biology, Tel Aviv University, Ph.D., Biochemistry, Tel Aviv University, Postdoctoral Fellow (Fulbright Scholar), Stanford University School of Medicine & HHMI, Graduate, Singularity University
- **Known for:** Fulbright Visiting Scholar (2007-2008) for postdoctoral research at Stanford University, Co-founded Genome Compiler and led its acquisition by Twist Bioscience (now ~$2.5B market cap, NASDAQ: TWST), Launched Tech.Bio pre-seed fund with early investments in breakout companies like Mammoth Biosciences

## Career timeline

- **2003-2007** — Ph.D. in Biochemistry at Tel Aviv University, studying membrane protein complexes in bio-energetics
- **2007-2011** — Fulbright Postdoctoral Fellow at Stanford University School of Medicine & HHMI in Prof. Axel Brunger's lab, working on neuroscience using structural and synthetic biology methods
- **2011** — Graduated from Singularity University; co-founded Genome Compiler, a CAD platform for synthetic biology ('AutoCAD for DNA')
- **2011-2016** — CEO of Genome Compiler, building collaboration tools for biotech, agriculture, and pharma researchers to design and compile biological sequences
- **2015** — Became mentor at IndieBio, the world's largest biotech accelerator
- **2016** — Genome Compiler acquired by Twist Bioscience (NASDAQ: TWST)
- **2016-2018** — Head of Corporate Development at Twist Bioscience post-acquisition
- **2018** — Launched Tech.Bio, a pre-seed venture fund at the intersection of biology and technology; early investments in Mammoth Biosciences, Immunai
- **2020** — Joined NFX as General Partner leading NFX Bio vertical; joined 8400 The Health Network
- **2022** — Co-founded Renewal Bio with Prof. Jacob Hanna (Weizmann Institute) to develop stem cell-derived synthetic embryo technologies for longevity and regenerative medicine
- **2024** — Joined board of Alliance for Longevity Initiatives (A4LI); spoke at Foresight Institute Vision Weekend and Longevity Biotech Fellowship
- **2025-2026** — Published 44+ NFX Library articles; speaking at SynBioBeta 2026; featured in We The Builders podcast; actively building Renewal Bio alongside NFX Bio portfolio of 15+ companies

## Achievements

- Fulbright Visiting Scholar (2007-2008) for postdoctoral research at Stanford University
- Co-founded Genome Compiler and led its acquisition by Twist Bioscience (now ~$2.5B market cap, NASDAQ: TWST)
- Launched Tech.Bio pre-seed fund with early investments in breakout companies like Mammoth Biosciences
- Built NFX Bio into a leading life sciences seed vertical with $1.4B AUM at parent fund
- Co-founded Renewal Bio with Weizmann Institute's Prof. Jacob Hanna, pioneering synthetic embryo technology
- Backed Centivax, which brought a universal flu vaccine candidate to clinic ($37M financing)
- Board member or chairman at 15+ biotech companies across NFX Bio portfolio
- Published 44+ long-form articles on biotech, longevity, and TechBio investing at NFX.com
- IndieBio mentor since 2015, helping shape 100+ biotech startups
- Member of Lifeboat Foundation advisory board on existential risk

## Latest updates

- **2026-05** — Speaking at SynBioBeta / Synthetic Biology Summit 2026 (May 5-6) on investor roundtable and fueling the bioeconomy
- **2026-02** — Featured in R136 Ventures interview series on longevity investing and seed VC mechanics
- **2026-01** — Published 'The Last Problem For AI to Solve is Health' and 'In Vitro, In Vivo, In China' on NFX
- **2025-07** — Featured on We The Builders podcast Episode 2: 'Investing at NFX, TechBio and Race To 160'
- **2024-12** — Featured on Biohacker Blondie podcast discussing Renewal Bio synthetic embryo technology
- **2024-09** — Presented at Foresight Institute Vision Weekend US 2024 and Longevity Biotech Fellowship on Renewal Bio

## Links

- Website: https://www.nfx.com/team/omri-amirav-drory
- LinkedIn: https://www.linkedin.com/in/omri-amirav-drory-50572727
- Twitter/X: https://x.com/omri_drory
- Instagram: https://www.instagram.com/amiravdrory/

---

Profile page: https://yespress.io/omri-amirav-drory
Published by YesPress — https://yespress.io
Last updated: 2026-05-01